|
|
ý
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
|
|
|
WISCONSIN
|
|
39-1506125
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(I. R. S. Employer
Identification No.)
|
255 FISERV DRIVE, BROOKFIELD, WI
|
|
53045
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
Large accelerated filer
|
ý
|
|
Accelerated filer
|
¨
|
Non-accelerated filer
|
¨
|
(Do not check if a smaller reporting company)
|
Smaller reporting company
|
¨
|
|
|
|
Emerging growth company
|
¨
|
|
|
|
Page
|
|
||
|
|
|
Item 1.
|
|
|
|
||
|
||
|
||
|
||
|
||
Item 2.
|
||
Item 3.
|
||
Item 4.
|
||
|
|
|
|
||
|
|
|
Item 1.
|
||
Item 2.
|
||
Item 6.
|
||
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, |
|
Six Months Ended
June 30, |
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Revenue:
|
|
|
|
|
|
|
|
||||||||
Processing and services
|
$
|
1,186
|
|
|
$
|
1,159
|
|
|
$
|
2,364
|
|
|
$
|
2,281
|
|
Product
|
200
|
|
|
204
|
|
|
416
|
|
|
413
|
|
||||
Total revenue
|
1,386
|
|
|
1,363
|
|
|
2,780
|
|
|
2,694
|
|
||||
Expenses:
|
|
|
|
|
|
|
|
||||||||
Cost of processing and services
|
573
|
|
|
547
|
|
|
1,143
|
|
|
1,100
|
|
||||
Cost of product
|
175
|
|
|
180
|
|
|
357
|
|
|
361
|
|
||||
Selling, general and administrative
|
276
|
|
|
274
|
|
|
553
|
|
|
532
|
|
||||
Gain on sale of business
|
(10
|
)
|
|
—
|
|
|
(10
|
)
|
|
—
|
|
||||
Total expenses
|
1,014
|
|
|
1,001
|
|
|
2,043
|
|
|
1,993
|
|
||||
Operating income
|
372
|
|
|
362
|
|
|
737
|
|
|
701
|
|
||||
Interest expense
|
(44
|
)
|
|
(40
|
)
|
|
(86
|
)
|
|
(80
|
)
|
||||
Interest and investment income (loss), net
|
2
|
|
|
—
|
|
|
2
|
|
|
(7
|
)
|
||||
Income before income taxes and income from investment in unconsolidated affiliate
|
330
|
|
|
322
|
|
|
653
|
|
|
614
|
|
||||
Income tax provision
|
(109
|
)
|
|
(110
|
)
|
|
(211
|
)
|
|
(259
|
)
|
||||
Income from investment in unconsolidated affiliate
|
—
|
|
|
—
|
|
|
26
|
|
|
146
|
|
||||
Net income
|
$
|
221
|
|
|
$
|
212
|
|
|
$
|
468
|
|
|
$
|
501
|
|
|
|
|
|
|
|
|
|
||||||||
Net income per share – basic
|
$
|
1.05
|
|
|
$
|
0.95
|
|
|
$
|
2.20
|
|
|
$
|
2.25
|
|
Net income per share – diluted
|
$
|
1.02
|
|
|
$
|
0.94
|
|
|
$
|
2.15
|
|
|
$
|
2.21
|
|
|
|
|
|
|
|
|
|
||||||||
Shares used in computing net income per share:
|
|
|
|
|
|
|
|
||||||||
Basic
|
211.8
|
|
|
222.0
|
|
|
213.2
|
|
|
222.8
|
|
||||
Diluted
|
216.3
|
|
|
225.6
|
|
|
217.8
|
|
|
226.5
|
|
|
Three Months Ended
June 30, |
|
Six Months Ended
June 30, |
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Net income
|
$
|
221
|
|
|
$
|
212
|
|
|
$
|
468
|
|
|
$
|
501
|
|
Other comprehensive income (loss):
|
|
|
|
|
|
|
|
||||||||
Fair market value adjustment on cash flow hedges, net of income tax provision of $1 million and $2 million
|
1
|
|
|
—
|
|
|
3
|
|
|
—
|
|
||||
Reclassification adjustment for net realized losses on cash flow hedges included in interest expense, net of income tax provision of $1 million, $1 million, $2 million and $2 million
|
1
|
|
|
1
|
|
|
3
|
|
|
3
|
|
||||
Foreign currency translation
|
6
|
|
|
(6
|
)
|
|
11
|
|
|
(3
|
)
|
||||
Total other comprehensive income (loss)
|
8
|
|
|
(5
|
)
|
|
17
|
|
|
—
|
|
||||
Comprehensive income
|
$
|
229
|
|
|
$
|
207
|
|
|
$
|
485
|
|
|
$
|
501
|
|
|
June 30,
2017 |
|
December 31,
2016 |
||||
Assets
|
|
|
|
||||
Cash and cash equivalents
|
$
|
299
|
|
|
$
|
300
|
|
Trade accounts receivable, net
|
845
|
|
|
902
|
|
||
Prepaid expenses and other current assets
|
488
|
|
|
526
|
|
||
Total current assets
|
1,632
|
|
|
1,728
|
|
||
Property and equipment, net
|
396
|
|
|
405
|
|
||
Intangible assets, net
|
1,807
|
|
|
1,833
|
|
||
Goodwill
|
5,435
|
|
|
5,373
|
|
||
Other long-term assets
|
415
|
|
|
404
|
|
||
Total assets
|
$
|
9,685
|
|
|
$
|
9,743
|
|
Liabilities and Shareholders’ Equity
|
|
|
|
||||
Accounts payable and accrued expenses
|
$
|
1,148
|
|
|
$
|
1,242
|
|
Current maturities of long-term debt
|
95
|
|
|
95
|
|
||
Deferred revenue
|
464
|
|
|
483
|
|
||
Total current liabilities
|
1,707
|
|
|
1,820
|
|
||
Long-term debt
|
4,646
|
|
|
4,467
|
|
||
Deferred income taxes
|
773
|
|
|
762
|
|
||
Other long-term liabilities
|
168
|
|
|
153
|
|
||
Total liabilities
|
7,294
|
|
|
7,202
|
|
||
Commitments and contingencies
|
|
|
|
||||
Shareholders’ equity:
|
|
|
|
||||
Preferred stock, no par value: 25.0 million shares authorized; none issued
|
—
|
|
|
—
|
|
||
Common stock, $0.01 par value: 900.0 million shares authorized; 395.7 million shares issued
|
4
|
|
|
4
|
|
||
Additional paid-in capital
|
1,017
|
|
|
1,020
|
|
||
Accumulated other comprehensive loss
|
(59
|
)
|
|
(76
|
)
|
||
Retained earnings
|
9,462
|
|
|
8,994
|
|
||
Treasury stock, at cost, 184.9 million and 180.2 million shares
|
(8,033
|
)
|
|
(7,401
|
)
|
||
Total shareholders’ equity
|
2,391
|
|
|
2,541
|
|
||
Total liabilities and shareholders’ equity
|
$
|
9,685
|
|
|
$
|
9,743
|
|
|
Six Months Ended
June 30, |
||||||
|
2017
|
|
2016
|
||||
Cash flows from operating activities:
|
|
|
|
||||
Net income
|
$
|
468
|
|
|
$
|
501
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
||||
Depreciation and other amortization
|
137
|
|
|
122
|
|
||
Amortization of acquisition-related intangible assets
|
78
|
|
|
80
|
|
||
Share-based compensation
|
33
|
|
|
39
|
|
||
Excess tax benefits from share-based awards
|
—
|
|
|
(37
|
)
|
||
Deferred income taxes
|
—
|
|
|
5
|
|
||
Income from investment in unconsolidated affiliate
|
(26
|
)
|
|
(146
|
)
|
||
Dividends from unconsolidated affiliate
|
31
|
|
|
140
|
|
||
Non-cash impairment charges
|
10
|
|
|
17
|
|
||
Gain on sale of business
|
(10
|
)
|
|
—
|
|
||
Other operating activities
|
(1
|
)
|
|
(2
|
)
|
||
Changes in assets and liabilities, net of effects from acquisitions:
|
|
|
|
||||
Trade accounts receivable
|
59
|
|
|
3
|
|
||
Prepaid expenses and other assets
|
(21
|
)
|
|
(38
|
)
|
||
Accounts payable and other liabilities
|
(47
|
)
|
|
37
|
|
||
Deferred revenue
|
(20
|
)
|
|
(34
|
)
|
||
Net cash provided by operating activities
|
691
|
|
|
687
|
|
||
Cash flows from investing activities:
|
|
|
|
||||
Capital expenditures, including capitalization of software costs
|
(136
|
)
|
|
(145
|
)
|
||
Payments for acquisitions of businesses, net of cash acquired
|
(78
|
)
|
|
(265
|
)
|
||
Proceeds from sale of business
|
19
|
|
|
—
|
|
||
Other investing activities
|
1
|
|
|
2
|
|
||
Net cash used in investing activities
|
(194
|
)
|
|
(408
|
)
|
||
Cash flows from financing activities:
|
|
|
|
||||
Debt proceeds
|
1,173
|
|
|
1,249
|
|
||
Debt repayments
|
(1,005
|
)
|
|
(991
|
)
|
||
Proceeds from issuance of treasury stock
|
47
|
|
|
47
|
|
||
Purchases of treasury stock, including employee shares withheld for tax obligations
|
(713
|
)
|
|
(633
|
)
|
||
Excess tax benefits from share-based awards
|
—
|
|
|
37
|
|
||
Net cash used in financing activities
|
(498
|
)
|
|
(291
|
)
|
||
Net change in cash and cash equivalents
|
(1
|
)
|
|
(12
|
)
|
||
Cash and cash equivalents, beginning balance
|
300
|
|
|
275
|
|
||
Cash and cash equivalents, ending balance
|
$
|
299
|
|
|
$
|
263
|
|
|
Six Months Ended
June 30, |
||||||||||||
|
2017
|
|
2016
|
||||||||||
|
Shares Granted
(In thousands) |
|
Weighted-Average Grant Date Fair Value
|
|
Shares Granted
(In thousands) |
|
Weighted-Average Grant Date Fair Value
|
||||||
Stock options
|
667
|
|
|
$
|
37.27
|
|
|
931
|
|
|
$
|
31.42
|
|
Restricted stock units
|
273
|
|
|
114.07
|
|
|
340
|
|
|
97.01
|
|
||
Performance share units
|
55
|
|
|
113.82
|
|
|
150
|
|
|
100.68
|
|
|
Three Months Ended
June 30, |
|
Six Months Ended
June 30, |
||||||||
(In millions)
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||
Weighted-average common shares outstanding used for the calculation of net income per share – basic
|
211.8
|
|
|
222.0
|
|
|
213.2
|
|
|
222.8
|
|
Common stock equivalents
|
4.5
|
|
|
3.6
|
|
|
4.6
|
|
|
3.7
|
|
Weighted-average common shares outstanding used for the calculation of net income per share – diluted
|
216.3
|
|
|
225.6
|
|
|
217.8
|
|
|
226.5
|
|
(In millions)
|
Gross
Carrying
Amount
|
|
Accumulated
Amortization
|
|
Net Book
Value
|
||||||
June 30, 2017
|
|
|
|||||||||
Customer related intangible assets
|
$
|
2,213
|
|
|
$
|
1,105
|
|
|
$
|
1,108
|
|
Acquired software and technology
|
525
|
|
|
445
|
|
|
80
|
|
|||
Trade names
|
117
|
|
|
61
|
|
|
56
|
|
|||
Capitalized software development costs
|
702
|
|
|
265
|
|
|
437
|
|
|||
Purchased software
|
230
|
|
|
104
|
|
|
126
|
|
|||
Total
|
$
|
3,787
|
|
|
$
|
1,980
|
|
|
$
|
1,807
|
|
(In millions)
|
Gross
Carrying
Amount
|
|
Accumulated
Amortization
|
|
Net Book
Value
|
||||||
December 31, 2016
|
|
|
|||||||||
Customer related intangible assets
|
$
|
2,200
|
|
|
$
|
1,043
|
|
|
$
|
1,157
|
|
Acquired software and technology
|
507
|
|
|
432
|
|
|
75
|
|
|||
Trade names
|
117
|
|
|
57
|
|
|
60
|
|
|||
Capitalized software development costs
|
641
|
|
|
233
|
|
|
408
|
|
|||
Purchased software
|
230
|
|
|
97
|
|
|
133
|
|
|||
Total
|
$
|
3,695
|
|
|
$
|
1,862
|
|
|
$
|
1,833
|
|
(In millions)
|
June 30,
2017 |
|
December 31,
2016 |
||||
Trade accounts payable
|
$
|
85
|
|
|
$
|
110
|
|
Client deposits
|
447
|
|
|
409
|
|
||
Settlement obligations
|
253
|
|
|
305
|
|
||
Accrued compensation and benefits
|
134
|
|
|
184
|
|
||
Other accrued expenses
|
229
|
|
|
234
|
|
||
Total
|
$
|
1,148
|
|
|
$
|
1,242
|
|
(In millions)
|
Cash Flow
Hedges
|
|
Foreign
Currency
Translation
|
|
Other
|
|
Total
|
||||||||
Balance at December 31, 2016
|
$
|
(24
|
)
|
|
$
|
(50
|
)
|
|
$
|
(2
|
)
|
|
$
|
(76
|
)
|
Other comprehensive income before reclassifications
|
3
|
|
|
11
|
|
|
—
|
|
|
14
|
|
||||
Amounts reclassified from accumulated other comprehensive loss
|
3
|
|
|
—
|
|
|
—
|
|
|
3
|
|
||||
Net current-period other comprehensive income
|
6
|
|
|
11
|
|
|
—
|
|
|
17
|
|
||||
Balance at June 30, 2017
|
$
|
(18
|
)
|
|
$
|
(39
|
)
|
|
$
|
(2
|
)
|
|
$
|
(59
|
)
|
(In millions)
|
Cash Flow
Hedges
|
|
Foreign
Currency
Translation
|
|
Other
|
|
Total
|
||||||||
Balance at December 31, 2015
|
$
|
(31
|
)
|
|
$
|
(41
|
)
|
|
$
|
(2
|
)
|
|
$
|
(74
|
)
|
Other comprehensive loss before reclassifications
|
—
|
|
|
(3
|
)
|
|
—
|
|
|
(3
|
)
|
||||
Amounts reclassified from accumulated other comprehensive loss
|
3
|
|
|
—
|
|
|
—
|
|
|
3
|
|
||||
Net current-period other comprehensive income (loss)
|
3
|
|
|
(3
|
)
|
|
—
|
|
|
—
|
|
||||
Balance at June 30, 2016
|
$
|
(28
|
)
|
|
$
|
(44
|
)
|
|
$
|
(2
|
)
|
|
$
|
(74
|
)
|
|
Six Months Ended
June 30, |
||||||
(In millions)
|
2017
|
|
2016
|
||||
Interest paid
|
$
|
77
|
|
|
$
|
72
|
|
Income taxes paid
|
206
|
|
|
203
|
|
||
Treasury stock purchases settled after the balance sheet date
|
13
|
|
|
24
|
|
(In millions)
|
Payments
|
|
Financial
|
|
Corporate
and Other
|
|
Total
|
||||||||
Three Months Ended June 30, 2017
|
|
|
|
|
|
|
|
||||||||
Processing and services revenue
|
$
|
602
|
|
|
$
|
582
|
|
|
$
|
2
|
|
|
$
|
1,186
|
|
Product revenue
|
177
|
|
|
41
|
|
|
(18
|
)
|
|
200
|
|
||||
Total revenue
|
$
|
779
|
|
|
$
|
623
|
|
|
$
|
(16
|
)
|
|
$
|
1,386
|
|
Operating income
|
$
|
238
|
|
|
$
|
214
|
|
|
$
|
(80
|
)
|
|
$
|
372
|
|
Three Months Ended June 30, 2016
|
|
|
|
|
|
|
|
||||||||
Processing and services revenue
|
$
|
587
|
|
|
$
|
570
|
|
|
$
|
2
|
|
|
$
|
1,159
|
|
Product revenue
|
176
|
|
|
42
|
|
|
(14
|
)
|
|
204
|
|
||||
Total revenue
|
$
|
763
|
|
|
$
|
612
|
|
|
$
|
(12
|
)
|
|
$
|
1,363
|
|
Operating income
|
$
|
237
|
|
|
$
|
202
|
|
|
$
|
(77
|
)
|
|
$
|
362
|
|
Six Months Ended June 30, 2017
|
|
|
|
|
|
|
|
||||||||
Processing and services revenue
|
$
|
1,197
|
|
|
$
|
1,162
|
|
|
$
|
5
|
|
|
$
|
2,364
|
|
Product revenue
|
376
|
|
|
81
|
|
|
(41
|
)
|
|
416
|
|
||||
Total revenue
|
$
|
1,573
|
|
|
$
|
1,243
|
|
|
$
|
(36
|
)
|
|
$
|
2,780
|
|
Operating income
|
$
|
497
|
|
|
$
|
410
|
|
|
$
|
(170
|
)
|
|
$
|
737
|
|
Six Months Ended June 30, 2016
|
|
|
|
|
|
|
|
||||||||
Processing and services revenue
|
$
|
1,147
|
|
|
$
|
1,131
|
|
|
$
|
3
|
|
|
$
|
2,281
|
|
Product revenue
|
365
|
|
|
80
|
|
|
(32
|
)
|
|
413
|
|
||||
Total revenue
|
$
|
1,512
|
|
|
$
|
1,211
|
|
|
$
|
(29
|
)
|
|
$
|
2,694
|
|
Operating income
|
$
|
462
|
|
|
$
|
397
|
|
|
$
|
(158
|
)
|
|
$
|
701
|
|
•
|
Overview.
This section contains background information on our company and the services and products that we provide, our enterprise priorities and the trends affecting our industry in order to provide context for management’s discussion and analysis of our financial condition and results of operations.
|
•
|
Results of operations.
This section contains an analysis of our results of operations presented in the accompanying unaudited consolidated statements of income by comparing the results for the
three and six months ended
June 30, 2017
to the comparable period in
2016
.
|
•
|
Liquidity and capital resources.
This section provides an analysis of our cash flows and a discussion of our outstanding debt as of
June 30, 2017
.
|
|
Three Months Ended June 30,
|
|||||||||||||||||||
|
2017
|
|
2016
|
|
Percentage of
Revenue (1)
|
|
Increase (Decrease)
|
|||||||||||||
(In millions)
|
2017
|
|
2016
|
|
$
|
|
%
|
|||||||||||||
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Processing and services
|
$
|
1,186
|
|
|
$
|
1,159
|
|
|
85.6
|
%
|
|
85.0
|
%
|
|
$
|
27
|
|
|
2
|
%
|
Product
|
200
|
|
|
204
|
|
|
14.4
|
%
|
|
15.0
|
%
|
|
(4
|
)
|
|
(2
|
)%
|
|||
Total revenue
|
1,386
|
|
|
1,363
|
|
|
100.0
|
%
|
|
100.0
|
%
|
|
23
|
|
|
2
|
%
|
|||
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Cost of processing and services
|
573
|
|
|
547
|
|
|
48.3
|
%
|
|
47.2
|
%
|
|
26
|
|
|
5
|
%
|
|||
Cost of product
|
175
|
|
|
180
|
|
|
87.5
|
%
|
|
88.2
|
%
|
|
(5
|
)
|
|
(3
|
)%
|
|||
Sub-total
|
748
|
|
|
727
|
|
|
54.0
|
%
|
|
53.3
|
%
|
|
21
|
|
|
3
|
%
|
|||
Selling, general and administrative
|
276
|
|
|
274
|
|
|
19.9
|
%
|
|
20.1
|
%
|
|
2
|
|
|
1
|
%
|
|||
Gain on sale of business
|
(10
|
)
|
|
—
|
|
|
(0.7
|
)%
|
|
—
|
|
|
10
|
|
|
—
|
|
|||
Total expenses
|
1,014
|
|
|
1,001
|
|
|
73.2
|
%
|
|
73.4
|
%
|
|
13
|
|
|
1
|
%
|
|||
Operating income
|
372
|
|
|
362
|
|
|
26.8
|
%
|
|
26.6
|
%
|
|
10
|
|
|
3
|
%
|
|||
Interest expense
|
(44
|
)
|
|
(40
|
)
|
|
(3.2
|
)%
|
|
(2.9
|
)%
|
|
4
|
|
|
10
|
%
|
|||
Interest and investment income, net
|
2
|
|
|
—
|
|
|
0.1
|
%
|
|
—
|
|
|
2
|
|
|
—
|
|
|||
Income before income taxes and income from investment in unconsolidated affiliate
|
$
|
330
|
|
|
$
|
322
|
|
|
23.8
|
%
|
|
23.6
|
%
|
|
$
|
8
|
|
|
2
|
%
|
|
Six Months Ended June 30,
|
|||||||||||||||||||
|
2017
|
|
2016
|
|
Percentage of
Revenue (1)
|
|
Increase (Decrease)
|
|||||||||||||
(In millions)
|
2017
|
|
2016
|
|
$
|
|
%
|
|||||||||||||
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Processing and services
|
$
|
2,364
|
|
|
$
|
2,281
|
|
|
85.0
|
%
|
|
84.7
|
%
|
|
$
|
83
|
|
|
4
|
%
|
Product
|
416
|
|
|
413
|
|
|
15.0
|
%
|
|
15.3
|
%
|
|
3
|
|
|
1
|
%
|
|||
Total revenue
|
2,780
|
|
|
2,694
|
|
|
100.0
|
%
|
|
100.0
|
%
|
|
86
|
|
|
3
|
%
|
|||
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Cost of processing and services
|
1,143
|
|
|
1,100
|
|
|
48.4
|
%
|
|
48.2
|
%
|
|
43
|
|
|
4
|
%
|
|||
Cost of product
|
357
|
|
|
361
|
|
|
85.8
|
%
|
|
87.4
|
%
|
|
(4
|
)
|
|
(1
|
)%
|
|||
Sub-total
|
1,500
|
|
|
1,461
|
|
|
54.0
|
%
|
|
54.2
|
%
|
|
39
|
|
|
3
|
%
|
|||
Selling, general and administrative
|
553
|
|
|
532
|
|
|
19.9
|
%
|
|
19.7
|
%
|
|
21
|
|
|
4
|
%
|
|||
Gain on sale of business
|
(10
|
)
|
|
—
|
|
|
(0.4
|
)%
|
|
—
|
|
|
10
|
|
|
—
|
|
|||
Total expenses
|
2,043
|
|
|
1,993
|
|
|
73.5
|
%
|
|
74.0
|
%
|
|
50
|
|
|
3
|
%
|
|||
Operating income
|
737
|
|
|
701
|
|
|
26.5
|
%
|
|
26.0
|
%
|
|
36
|
|
|
5
|
%
|
|||
Interest expense
|
(86
|
)
|
|
(80
|
)
|
|
(3.1
|
)%
|
|
(3.0
|
)%
|
|
6
|
|
|
8
|
%
|
|||
Interest and investment income (loss), net
|
2
|
|
|
(7
|
)
|
|
0.1
|
%
|
|
(0.3
|
)%
|
|
9
|
|
|
129
|
%
|
|||
Income before income taxes and income from investment in unconsolidated affiliate
|
$
|
653
|
|
|
$
|
614
|
|
|
23.5
|
%
|
|
22.8
|
%
|
|
$
|
39
|
|
|
6
|
%
|
(1)
|
Percentage of revenue is calculated as the relevant revenue, expense, income or loss amount divided by total revenue, except for cost of processing and services and cost of product amounts which are divided by the related component of revenue.
|
(1)
|
Represents the basis point growth or decline in operating margin.
|
|
Six Months Ended
June 30, |
|
Increase (Decrease)
|
|||||||||||
(In millions)
|
2017
|
|
2016
|
|
$
|
|
%
|
|||||||
Net income
|
$
|
468
|
|
|
$
|
501
|
|
|
$
|
(33
|
)
|
|
|
|
Depreciation and amortization
|
215
|
|
|
202
|
|
|
13
|
|
|
|
||||
Share-based compensation
|
33
|
|
|
39
|
|
|
(6
|
)
|
|
|
||||
Excess tax benefits from share-based awards
|
—
|
|
|
(37
|
)
|
|
37
|
|
|
|
||||
Deferred income taxes
|
—
|
|
|
5
|
|
|
(5
|
)
|
|
|
||||
Income from investment in unconsolidated affiliate
|
(26
|
)
|
|
(146
|
)
|
|
120
|
|
|
|
||||
Dividends from unconsolidated affiliate
|
31
|
|
|
140
|
|
|
(109
|
)
|
|
|
||||
Non-cash impairment charges
|
10
|
|
|
17
|
|
|
(7
|
)
|
|
|
||||
Gain on sale of business
|
(10
|
)
|
|
—
|
|
|
(10
|
)
|
|
|
||||
Net changes in working capital and other
|
(30
|
)
|
|
(34
|
)
|
|
4
|
|
|
|
||||
Operating cash flow
|
$
|
691
|
|
|
$
|
687
|
|
|
$
|
4
|
|
|
1
|
%
|
Capital expenditures
|
$
|
136
|
|
|
$
|
145
|
|
|
$
|
(9
|
)
|
|
(6
|
)%
|
(In millions)
|
June 30,
2017 |
|
December 31, 2016
|
||||
Revolving credit facility
|
$
|
819
|
|
|
$
|
647
|
|
Term loan
|
629
|
|
|
629
|
|
||
2.7% senior notes due 2020
|
845
|
|
|
845
|
|
||
4.625% senior notes due 2020
|
448
|
|
|
448
|
|
||
4.75% senior notes due 2021
|
398
|
|
|
398
|
|
||
3.5% senior notes due 2022
|
695
|
|
|
695
|
|
||
3.85% senior notes due 2025
|
894
|
|
|
893
|
|
||
Other borrowings
|
13
|
|
|
7
|
|
||
Total debt (including current maturities)
|
$
|
4,741
|
|
|
$
|
4,562
|
|
Period
|
Total Number of
Shares Purchased
|
|
Average Price
Paid per Share
|
|
Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs (1)
|
|
Maximum Number
of Shares that May
Yet Be Purchased
Under the Plans or
Programs (1)
|
|||||
April 1-30, 2017
|
855,000
|
|
|
$
|
117.17
|
|
|
855,000
|
|
|
16,193,000
|
|
May 1-31, 2017
|
915,000
|
|
|
120.68
|
|
|
915,000
|
|
|
15,278,000
|
|
|
June 1-30, 2017
|
680,000
|
|
|
124.19
|
|
|
680,000
|
|
|
14,598,000
|
|
|
Total
|
2,450,000
|
|
|
|
|
2,450,000
|
|
|
|
(1)
|
On each of November 18, 2015 and November 16, 2016, our board of directors authorized the purchase of up to 15.0 million shares of our common stock. These authorizations do not expire.
|
|
|
|
|
|
|
|
FISERV, INC.
|
||
|
|
|
|
|
Date:
|
August 2, 2017
|
By:
|
|
/s/ Robert W. Hau
|
|
|
|
|
Robert W. Hau
|
|
|
|
|
Chief Financial Officer and Treasurer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date:
|
August 2, 2017
|
By:
|
|
/s/ Kenneth F. Best
|
|
|
|
|
Kenneth F. Best
|
|
|
|
|
Chief Accounting Officer
|
Exhibit
Number
|
|
Exhibit Description
|
|
|
|
10.1
|
|
Form of Amendment to Non-Qualified Stock Option Agreement (Non-Employee Director - LE)
|
|
|
|
10.2
|
|
Form of Non-Qualified Stock Option Agreement (Non-Employee Director - EE)
|
|
|
|
31.1
|
|
Certification of the Chief Executive Officer, dated August 2, 2017
|
|
|
|
31.2
|
|
Certification of the Chief Financial Officer, dated August 2, 2017
|
|
|
|
32
|
|
Certification of the Chief Executive Officer and Chief Financial Officer, dated August 2, 2017
|
|
|
|
101.INS*
|
|
XBRL Instance Document
|
|
|
|
101.SCH*
|
|
XBRL Taxonomy Extension Schema Document
|
|
|
|
101.CAL*
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
|
101.DEF*
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
|
101.LAB*
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
|
|
101.PRE*
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
*
|
Filed with this quarterly report on Form 10-Q are the following documents formatted in XBRL (Extensible Business Reporting Language): (i) the Consolidated Statements of Income for the
three and six months ended
June 30, 2017
and
2016
, (ii) the Consolidated Statements of Comprehensive Income for the
three and six months ended
June 30, 2017
and
2016
, (iii) the Consolidated Balance Sheets at
June 30, 2017
and
December 31, 2016
, (iv) the Consolidated Statements of Cash Flows for the
six
months ended
June 30, 2017
and
2016
, and (v) Notes to Consolidated Financial Statements.
|
6.
|
Termination of Directorship.
|
(a)
|
Vesting
. If you cease to be a Director for any reason other than for Cause, the Option may be exercised to the same extent that you were entitled to exercise the Option on the date you ceased to be a Director and had not previously done so, and the unvested Option Shares will immediately terminate and expire.
|
(b)
|
Deadline for Exercise
.
|
(i)
|
If you cease to be a Director by reason of Retirement, you are (or in the event your Retirement is by reason of your death or Disability resulting in judicial appointment of a guardian ad litem, administrator or other legal representative, the executor or administrator of your estate, any person who shall have acquired the Option through bequest or inheritance or such guardian ad litem, administrator or other legal representative is) entitled to exercise the Option per the terms contained herein within five years following your cessation of service as a Director.
|
(ii)
|
If you cease to be a Director by reason of death or Disability and you are not eligible for Retirement, you are (or in the event of your death or Disability resulting in judicial appointment of a guardian ad litem, administrator or other legal representative, the executor or administrator of your estate, any person who shall have acquired the Option through bequest or inheritance or such guardian ad litem, administrator or other legal representative is) entitled to exercise the Option per the terms contained herein within one year after you cease to be a Director.
|
(iii)
|
Subject to Section 6(d), if you cease to be a Director for any reason other than death, Disability or Retirement, you are entitled to exercise the Option per the terms contained herein within 90 days after you cease to be a Director.
|
(iv)
|
If you die within the exercise period described in subsection (i) above, your executor, the administrator of your estate or your beneficiary may exercise the Option within the longer of (A) one year after your death or (B) five years following your cessation of service as a Director. If you die within the exercise periods described in subsections (ii) and (iii) above, your executor, the administrator of your estate or your beneficiary may exercise the Option within one year after your death.
|
(v)
|
“
Retirement
” means the cessation of service as a director for any reason, including death or Disability, other than termination for Cause, on or after the date: (A) you are at least 60 years of age and your age plus years of service to the Company and its subsidiaries is equal to or greater than 70; or (B) you are least 65 years of age.
|
By
|
|
|
Name:
|
|
Title:
|
|
|
|
Non-Employee Director:
|
|
[FIRST NAME] [LAST NAME]
|
|
|
|
Grant Date:
|
|
[GRANT DATE]
|
|
|
|
Number of Shares Subject to Option:
|
|
[NUMBER OF SHARES]
|
|
|
|
Exercise Price Per Option Share:
|
|
[EXERCISE PRICE]
|
|
|
|
Type of Option:
|
|
Non-Qualified Stock Option
|
|
|
|
Vesting Schedule:
|
|
The Option will vest 100% on the earlier of (a) immediately prior to first annual meeting of shareholders after the Grant Date or (b) the first anniversary of the Grant Date.
|
|
|
|
Expiration Date:
|
|
10 years after the Grant Date
|
1.
|
Grant Date; Type of Option
.
The Option is granted to you on the Grant Date set forth in the Award Memorandum. As a “non-qualified stock option,” the Option will not be treated by you or the Company as an incentive stock option as defined in Section 422 of the Code.
|
2.
|
Termination of Option
.
Your right to exercise the Option and to purchase the Option Shares shall expire and terminate in all events on the earliest of (a) the Expiration Date set forth in the Award Memorandum or (b) the date upon which exercise is no longer permitted pursuant to Section 6 of this Agreement or (c) your failure to accept the terms of this Agreement, the Award Memorandum and the Plan within the time period and in the manner specified in this Agreement.
|
3.
|
Exercise Price
.
The purchase price to be paid upon the exercise of the Option will be the Exercise Price Per Option Share set forth in the Award Memorandum.
|
4.
|
Vesting; Provisions Relating to Exercise.
Once you become entitled to exercise any part of the Option (and to purchase Option Shares) pursuant to the vesting schedule set forth in the Award Memorandum, that right will continue until the date on which the Option expires and terminates. The right to purchase Option Shares under the Option is cumulative, so that if the full number of Option Shares is not purchased in a single transaction, the balance may be purchased at any time or from time to time thereafter during the term of the Option. The Administrator, in its sole discretion, may at any time accelerate the time at which the Option becomes exercisable by you with respect to any Option Shares. The Company may cancel, rescind, suspend, withhold or otherwise limit or restrict any unexpired, unpaid or deferred part of the Option at any time if you are not in compliance with all applicable provisions of this Agreement, the Award Memorandum and the Plan.
|
5.
|
Exercise of Option.
To exercise the Option, you must complete the transaction through our administrative agent’s website at www.netbenefits.fidelity.com or call its toll free number at (800) 544-9354, specifying the number of Option Shares being purchased as a result of such exercise, and make payment of the full Exercise Price for the Option Shares being purchased. In no event may a fraction of a share be exercised or acquired. You must also pay any taxes or other amounts required to be withheld as provided in Section 13 of this Agreement.
|
6.
|
Termination of Directorship.
|
(a)
|
Vesting
. If you cease to be a Director for any reason other than for Cause, the Option may be exercised to the same extent that you were entitled to exercise the Option on the date you ceased to be a Director and had not previously done so, and the unvested Option Shares will immediately terminate and expire.
|
(b)
|
Deadline for Exercise
.
|
(i)
|
If you cease to be a Director by reason of Retirement, you are (or in the event your Retirement is by reason of your death or Disability resulting in judicial appointment of a guardian ad litem, administrator or other legal representative, the executor or administrator of your estate, any person who shall have acquired the Option through bequest or inheritance or such guardian ad litem, administrator or other legal
|
(ii)
|
If you cease to be a Director by reason of death or Disability and you are not eligible for Retirement, you are (or in the event of your death or Disability resulting in judicial appointment of a guardian ad litem, administrator or other legal representative, the executor or administrator of your estate, any person who shall have acquired the Option through bequest or inheritance or such guardian ad litem, administrator or other legal representative is) entitled to exercise the Option per the terms contained herein within one year after you cease to be a Director.
|
(iii)
|
Subject to Section 6(d), if you cease to be a Director for any reason other than death, Disability or Retirement, you are entitled to exercise the Option per the terms contained herein within 90 days after you cease to be a Director.
|
(iv)
|
If you die within the exercise period described in subsection (i) above, your executor, the administrator of your estate or your beneficiary may exercise the Option within the longer of (A) one year after your death or (B) five years following your cessation of service as a Director. If you die within the exercise periods described in subsections (ii) and (iii) above, your executor, the administrator of your estate or your beneficiary may exercise the Option within one year after your death.
|
(v)
|
“
Retirement
” means the cessation of service as a director for any reason, including death or Disability, other than termination for Cause, on or after the date: (A) you are at least 60 years of age and your age plus years of service to the Company and its subsidiaries is equal to or greater than 70; or (B) you are least 65 years of age.
|
(c)
|
Expiration
. Notwithstanding any provision contained in this Section 6 to the contrary, in no event may the Option be exercised to any extent by anyone after the Expiration Date set forth in the Award Memorandum.
|
(d)
|
Termination for Cause
. If your service as a Director is terminated for Cause, the Option, whether or not vested, shall terminate immediately. In addition, if your service as a Director is terminated other than for Cause but the Administrator later determines that it could have been terminated for Cause if all facts had been known at the time you were terminated, the Option, whether or not vested, will terminate immediately on the date of such determination.
|
(e)
|
Change of Control
. If a Change of Control of the Company occurs, the provisions of Section 17(c) of the Plan shall apply to the Option.
|
(f)
|
No Further Obligation
. The Company will have no further obligation to you under this Agreement if the Option ceases to become exercisable as provided herein.
|
7.
|
Issuance of Shares
. The Company, or its transfer agent, will issue and deliver the Option Shares to you as soon as practicable after you exercise any part of the Option and pay the Exercise Price Per Option Share and all applicable related withholding taxes, if any. If you die before the Company has distributed any portion of the Option Shares purchased upon exercise, the Company will issue the Option Shares to your estate or in accordance with applicable laws of descent and distribution. The Option Shares will be issued in book entry form, and the Company will not be liable for damages relating to any delays in making an appropriate book entry or any mistakes or errors in the making of the book entry; provided that the Company shall correct any errors caused by it. Any such book entry will be subject to such stop transfer orders and other restrictions as the Company may deem advisable under (a) the Plan and any agreement between you and the Company with respect to the Option Shares, (b) any applicable federal or state laws, and/or (c) the rules, regulations and other requirements of the Securities and Exchange Commission (“
SEC
”) or any stock exchange upon which the Option Shares are listed. The Company may cause an appropriate book entry notation to be made with respect to the Option Shares to reference any of the foregoing restrictions.
|
8.
|
Non-Transferability of Award
. Except as provided in the Plan, this Agreement and the Award Memorandum, until the Option Shares have been purchased upon exercise of any part of this Option, this Option and the Option Shares issuable upon exercise hereunder and the rights and privileges conferred hereby may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated (by operation of law or otherwise). Upon any attempt to transfer, assign, pledge, hypothecate or otherwise dispose of this Option, or of any right or privilege conferred hereby, contrary to the provisions of the Plan or of this Agreement, or upon any attempted sale under any execution, attachment or similar process upon the rights and privileges conferred hereby, this Option and the rights and privileges conferred hereby shall immediately become null and void.
|
9.
|
Conditions to Issuance of Shares
. The Option Shares issued to you hereunder upon exercise and purchase may be either previously authorized but unissued shares or issued shares which have been reacquired by the Company. The Company shall not be required to issue any Option Shares hereunder prior to fulfillment of all of the following conditions: (a) the admission of such Option Shares to listing on all stock exchanges on which such class of stock is then listed; (b) the completion of any registration or other qualification of such Option Shares under any state or federal law or under the rulings or regulations of the SEC or any other governmental regulatory body, which the compensation committee of the Board of Directors (the “
Compensation Committee
”) shall, in its discretion, deem necessary or advisable; (c) the obtaining of any approval or other clearance from any state or federal governmental agency, which the Compensation Committee shall, in its discretion, determine to be necessary or advisable; (d) the lapse of such reasonable period of time following the exercise of the Option as the Compensation Committee may establish from time to time for reasons of administrative convenience; and (e) your acceptance of the terms and conditions of this Agreement, the Award Memorandum and the Plan within the time period and in the manner specified in this Agreement.
|
10.
|
No Rights as Shareholder
.
Until you exercise any part of this Option, purchase Option Shares and the Option Shares are issued to you, you shall have no rights as a shareholder of the Company with respect to the Option Shares. Specifically, you understand and agree that you do not have voting rights or the right to receive dividends or any other distributions paid with respect to shares of Company common stock by virtue of this Option or the Option Shares subject hereto.
|
11.
|
Addresses for Notices
. Any notice to be given to the Company under the terms of this Agreement shall be addressed to the Company as follows: Corporate Secretary, Fiserv, Inc., 255 Fiserv Drive, Brookfield, WI 53045, or at such other address as the Company may hereafter designate in writing. Any notice to be given to the Director shall be addressed to the Director at the address set forth in the Company’s records from time to time.
|
12.
|
Captions; Agreement Severable
. Captions provided herein are for convenience only and are not to serve as a basis for interpretation or construction of this Agreement. In the event that any provision in this Agreement shall be held invalid or unenforceable, such provision shall be severable from, and such invalidity or unenforceability shall not be construed to have any effect on, the remaining provisions of this Agreement.
|
13.
|
Securities and Tax Representations
.
|
(a)
|
You acknowledge receipt of the prospectus under the Registration Statement on Form S-8 with respect to the Plan filed by the Company with the SEC. You represent and agree that you will comply with all applicable laws and Company policies relating to the Plan, this Agreement, the exercise of the Option and any disposition of the Option Shares, and that upon the acquisition of any Option Shares, you will make or enter into such written representations, warranties and agreements as the Company may reasonably request to comply with applicable securities laws or this Agreement.
|
(b)
|
You represent and warrant that you understand the federal, state and local income tax consequences of the granting of the Option, the exercise of the Option, the purchase of Option Shares, and the subsequent sale or other disposition of any Option Shares. Unless required by law, the Company will not withhold any federal, state or local income taxes in connection with the Option Shares. You understand and agree that you are solely responsible
|
14.
|
Market Stand-Off
.
The Company reserves the right to impose restrictions on dispositions in connection with any underwritten public offering by the Company of its equity securities pursuant to an effective registration statement filed under the Securities Act of 1933, as amended. Upon receipt of written notice from the Company of a trading restriction, you agree that you shall not directly or indirectly sell, make any short sale of, loan, hypothecate, pledge, offer, grant or sell any option or other contract for the purchase of, purchase any option or other contract for the sale of, or otherwise dispose of or transfer or agree to engage in any of the foregoing transactions with respect to, any Option Shares acquired under this Option without the prior written consent of the Company. Such restriction shall be in effect for such period of time following the date of the final prospectus for the offering as may be determined by the Company. In no event, however, shall such period exceed one hundred eighty (180) days.
|
15.
|
General Provisions
.
|
(a)
|
None of the Plan, this Agreement or the Award Memorandum confers upon you any right to continue to serve as a Director.
|
(b)
|
This Agreement, the Award Memorandum and the Plan contain the entire agreement between the Company and you relating to the Option and supersede all prior agreements or understandings relating thereto.
|
(c)
|
This Agreement and the Award Memorandum may only be modified, amended or cancelled as provided in the Plan.
|
(d)
|
If any one or more provisions of this Agreement or the Award Memorandum is found to be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions hereof shall not in any way be affected or impaired thereby.
|
(e)
|
Any remedies available to the Company under the Plan or this Agreement are cumulative and are in addition to, and are not affected by, the other rights and remedies available to the Company under the Plan, this Agreement, by law or otherwise.
|
(f)
|
This Agreement and the Award Memorandum shall be governed by and construed in accordance with the laws of the State of Wisconsin, without regard to conflict of law provisions.
|
(g)
|
The Company agrees, and you agree, to be subject to and bound by all of the terms and conditions of the Plan. The Prospectus for the Plan is accessible on the administrative agent’s website (
www.netbenefits.fidelity.com
) in the “forms library” and a paper copy is available upon request.
|
(h)
|
During your lifetime, the Option may only be exercised by you or your legal representatives.
|
(i)
|
This Agreement and the Award Memorandum shall be binding upon and inure to the benefit of any successor or assign of the Company and to any heir, distributee, executor, administrator or legal representative entitled by law to your rights hereunder.
|
(j)
|
You understand that, under the terms of the Plan, this Agreement and the Award Memorandum, the Company may cancel or rescind the Option and/or the Option Shares in certain circumstances.
|
1.
|
I have reviewed this quarterly report on Form 10-Q of Fiserv, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
|
|
|
|
|
|
Date:
|
August 2, 2017
|
|
By:
|
|
/s/ Jeffery W. Yabuki
|
|
|
|
|
|
Jeffery W. Yabuki
|
|
|
|
|
|
President and Chief Executive Officer
|
1.
|
I have reviewed this quarterly report on Form 10-Q of Fiserv, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
|
|
|
|
|
|
Date:
|
August 2, 2017
|
|
By:
|
|
/s/ Robert W. Hau
|
|
|
|
|
|
Robert W. Hau
|
|
|
|
|
|
Chief Financial Officer and Treasurer
|
(1)
|
The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and
|
(2)
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
|
|
By:
|
|
/s/ Jeffery W. Yabuki
|
|
|
Jeffery W. Yabuki
|
|
|
August 2, 2017
|
|
|
|
By:
|
|
/s/ Robert W. Hau
|
|
|
Robert W. Hau
|
|
|
August 2, 2017
|